EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
Business of Merck KGaA, Darmstadt, Germany.
Clin Pharmacol Ther. 2020 Oct;108(4):699-702. doi: 10.1002/cpt.1879. Epub 2020 May 28.
The unprecedented challenges posed by the coronavirus disease 2019 (COVID-19) pandemic highlight the urgency for applying clinical pharmacology and model-informed drug development in (i) dosage optimization for COVID-19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non-COVID-19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development, and regulation.
由 2019 年冠状病毒病(COVID-19)大流行带来的前所未有的挑战突显了临床药理学和基于模型的药物开发在以下方面的紧迫性:(i)COVID-19 治疗的剂量优化,(ii)在临床试验环境中解决治疗难题,以及(iii)从受影响的非 COVID-19 试验中最大限度地获取信息。在这场与时间赛跑的生物医学研究、临床实践、药物开发和监管的竞赛中,我们比以往任何时候都更有责任采用基于全证据的适应性证据综合方法。